OPRM1 Protein, Human (Cell-Free, His)

OPRM1 serves as a receptor for a range of endogenous opioids, including beta-endorphin and endomorphin, as well as responding to various natural and synthetic opioids like morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphine, and methadone. Upon agonist binding, the receptor undergoes conformational changes, leading to the activation of downstream signaling cascades. Agonist-induced activation involves coupling to an inactive GDP-bound heterotrimeric G-protein complex, initiating dissociation of the G-protein complex, and subsequent activation of G-protein alpha subunits, particularly the pertussis toxin-sensitive G(i) and G(o) G alpha proteins. This activation leads to a multitude of cellular responses, including the inhibition of adenylate cyclase activity, modulation of calcium channels, activation of potassium channels, and regulation of various intracellular signaling pathways such as MAPK, PLC, PKC, PI3K, and NF-kappa-B. Additionally, OPRM1 undergoes phosphorylation by GPRK subfamily protein kinases, and its association with beta-arrestins is crucial for short-term receptor desensitization, internalization through endocytosis, and subsequent recycling. The receptor, acting as a class A G-protein coupled receptor (GPCR), exhibits selective temporal coupling to G-proteins and undergoes rapid recycling, while its down-regulation pathways vary with the agonist and can occur dependent or independent of G-protein coupling. Furthermore, OPRM1 has the potential for heterooligomerization with other GPCRs, influencing agonist binding, signaling, and trafficking properties, ultimately playing a role in excitatory effects.